Sangamo Therapeutics Management

Management Kriterienprüfungen 3/4

Sangamo Therapeutics CEO ist Sandy Macrae , ernannt in Jun 2016, hat eine Amtszeit von 8.42 Jahren. Die jährliche Gesamtvergütung beträgt $2.39M , bestehend aus 29.9% Gehalt und 70.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.19% der Aktien des Unternehmens, im Wert von $853.51K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.3 Jahre bzw. 5 Jahre.

Wichtige Informationen

Sandy Macrae

Geschäftsführender

US$2.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	29.9%
Amtszeit als Geschäftsführer	8.4yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	3.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sandy Macrae im Vergleich zu den Einnahmen von Sangamo Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$135m
Jun 30 2024	n/a	n/a	-US$250m
Mar 31 2024	n/a	n/a	-US$328m
Dec 31 2023	US$2m	US$716k	-US$258m
Sep 30 2023	n/a	n/a	-US$250m
Jun 30 2023	n/a	n/a	-US$199m
Mar 31 2023	n/a	n/a	-US$127m
Dec 31 2022	US$5m	US$709k	-US$192m
Sep 30 2022	n/a	n/a	-US$178m
Jun 30 2022	n/a	n/a	-US$172m
Mar 31 2022	n/a	n/a	-US$176m
Dec 31 2021	US$5m	US$689k	-US$178m
Sep 30 2021	n/a	n/a	-US$181m
Jun 30 2021	n/a	n/a	-US$135m
Mar 31 2021	n/a	n/a	-US$124m
Dec 31 2020	US$4m	US$682k	-US$121m
Sep 30 2020	n/a	n/a	-US$76m
Jun 30 2020	n/a	n/a	-US$102m
Mar 31 2020	n/a	n/a	-US$96m
Dec 31 2019	US$4m	US$662k	-US$95m
Sep 30 2019	n/a	n/a	-US$118m
Jun 30 2019	n/a	n/a	-US$104m
Mar 31 2019	n/a	n/a	-US$90m
Dec 31 2018	US$4m	US$636k	-US$68m
Sep 30 2018	n/a	n/a	-US$63m
Jun 30 2018	n/a	n/a	-US$62m
Mar 31 2018	n/a	n/a	-US$58m
Dec 31 2017	US$2m	US$612k	-US$55m

Vergütung im Vergleich zum Markt: SandyDie Gesamtvergütung ($USD2.39M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD993.01K).

Entschädigung vs. Einkommen: SandyDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Sandy Macrae (61 yo)

8.4yrs

Amtszeit

US$2,392,272

Vergütung

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Alexander Macrae	CEO, President & Director	8.4yrs	US$2.39m	0.19% $ 853.5k
Prathyusha Duraibabu	Senior VP	5.4yrs	US$1.06m	0.036% $ 160.8k
Nathalie Dubois-Stringfellow	Senior VP & Chief Development Officer	5.8yrs	US$1.03m	0.044% $ 195.7k
Gregory Davis	Head of Technology	less than a year	keine Daten	0.018% $ 82.1k
Aron Feingold	Head of Corporate Communications & Investor Relations Officer	no data	keine Daten	keine Daten
Scott Willoughby	Senior VP	3.3yrs	keine Daten	0.041% $ 184.8k
Phillip Ramsey	Head of Technical Operations	1.5yrs	keine Daten	keine Daten
Stephanie J. Seiler	Head of Business Development & Alliance Management	less than a year	keine Daten	keine Daten
David Ojala	Scientist II - Discovery & Translational Research	no data	keine Daten	keine Daten
Louise Wilkie	Vice President of Investor Relations & Corporate Communications	no data	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: 0R1DDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Alexander Macrae	CEO, President & Director	8.4yrs	US$2.39m	0.19% $ 853.5k
H. Parker	Independent Chairwoman of the Board	10.4yrs	US$99.28k	0.030% $ 134.8k
Robert Carey	Independent Director	8.4yrs	US$80.53k	0.024% $ 106.8k
Stuart Schreiber	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Robert Desnick	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Roger Kornberg	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Samuel A. J. Aparicio	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Jef Boeke	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Karen Smith	Independent Director	6.4yrs	US$76.78k	0.025% $ 112.2k
Megan Levings	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Michael Grunstein	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten
Douglas Higgs	Member of Scientific Advisory Board	5yrs	keine Daten	keine Daten

5.0yrs

Durchschnittliche Betriebszugehörigkeit

66.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 0R1DDie Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).

Sangamo Therapeutics Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer

Sangamo Therapeutics, Inc. Announces Directors Appointment

Insufficient new directors

Sangamo Therapeutics, Inc Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.59 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

New major risk - Financial position

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.66 loss in 2Q 2023)

Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Market cap size

New major risk - Financial position

Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.

Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.

Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings released: US$1.48 loss per share (vs US$1.25 loss in FY 2022)

Sangamo Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920

Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial

Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023

Sangamo Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy

New minor risk - Market cap size

New major risk - Financial position

Second quarter 2023 earnings released: US$0.66 loss per share (vs US$0.29 loss in 2Q 2022)

Sangamo Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer

First quarter 2023 earnings released: EPS: US$0.13 (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.25 loss per share (vs US$1.23 loss in FY 2021)

Sangamo Therapeutics, Inc. Announces Directors Appointment

Insufficient new directors

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 3Q 2021)

Sangamo Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Five Longest Treated Patients

Sangamo Therapeutics, Inc Announces Executive Changes

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.33 loss in 2Q 2021)

Sangamo Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.32 loss in 1Q 2021)

Sangamo Therapeutics, Inc. to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

High number of new and inexperienced directors

Saira Ramasastry Decides Not to Stand for Re-Election as A Member of the Board of Directors of Sangamo Therapeutics, Inc

Sangamo Therapeutics, Inc., Annual General Meeting, May 24, 2022

Sangamo Therapeutics, Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

Sangamo Therapeutics, Inc. Doses First Patient in Its Phase 1/2 STEADFAST Clinical Study Evaluating TX200

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sangamo Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Patients with Fabry Disease

Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.011 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.26 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.37 loss in 1Q 2020)

Executive VP recently sold US$73k worth of stock

Sangamo Therapeutics, Inc. Appoints Prathyusha Duraibabu as Principal Financial Officer

Full year 2020 earnings released: US$0.90 loss per share (vs US$0.85 loss in FY 2019)

Revenue misses expectations

Sangamo Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Executive VP & CFO has left the company

Sangamo Therapeutics Appoints Rob Schott as Senior Vice President and Head of Development

Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee, Effective February 1, 2021

Insider recently sold US$60k worth of stock

Third quarter 2020 earnings released: US$0.011 loss per share

Revenue beats expectations

Sangamo Therapeutics, Inc. to Report Q3, 2020 Results on Nov 04, 2020

Pfizer Inc. and Sangamo Therapeutics, Inc. Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment

Sangamo Therapeutics, Inc. Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019

Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.